Cite
HARVARD Citation
Michallet, A. et al. (2019). Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial. Lancet. 6 (9), pp. e470-e479. [Online].